More long-term studies are warranted to evaluate whether the same daily dose in different formulations leads to distinct increases in muscle carnosine content
Waldman M, Arad M, Abraham NG, Hochhauser E
In the PIONEER 3 trial published in JAMA, 1,864 patients were randomised to oral semaglutide (3 mg, 7 mg, or 14 mg) or sitagliptin 100 mg
Whether one is worth the wait depends on your complexity and your coverage
The primary aim of the present trial was to compare the effects of liraglutide 1.8 and 3.0 mg, the maximum approved dose in treatment of type 2 diabetes and the intended clinical dose in weight management, respectively, on gastric emptying in obese individuals without T2DM, with the focus on demonstrating equivalence between the two doses over a 5-h period, in order to support that no dose adjustment of concomitantly administered oral medications would be required during treatment with liraglutide 3.0 mg